Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells 808 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 808 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $19.79, for a total value of $15,990.32. Following the transaction, the chief financial officer directly owned 118,334 shares in the company, valued at $2,341,829.86. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Scott Blumberg also recently made the following trade(s):

• On Monday, December 22nd, Scott Blumberg sold 36,000 shares of CeriBell stock. The shares were sold at an average price of $21.00, for a total transaction of $756,000.00.

CeriBell Stock Down 4.8%

Shares of NASDAQ CBLL traded down $0.95 during trading on Wednesday, reaching $18.95. 713,550 shares of the stock were exchanged, compared to its average volume of 351,326. The company has a market capitalization of $703.05 million, a price-to-earnings ratio of -12.55 and a beta of 1.03. The business’s 50-day moving average price is $21.26 and its 200 day moving average price is $16.17. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $25.98.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. As a group, equities analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several large investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its holdings in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the period. CWM LLC boosted its stake in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after buying an additional 1,256 shares during the period. Finally, Larson Financial Group LLC increased its holdings in shares of CeriBell by 1,403.1% in the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock worth $63,000 after acquiring an additional 2,680 shares during the period.

Wall Street Analyst Weigh In

CBLL has been the subject of several research analyst reports. JPMorgan Chase & Co. reduced their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. BTIG Research reiterated a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. TD Cowen reissued a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Finally, Canaccord Genuity Group upped their target price on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Key Headlines Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on both EPS and revenue — CeriBell reported a loss of ($0.36) vs. consensus ($0.43) and revenue of $24.78M vs. $23.95M expectations, showing top‑line strength and a smaller-than-expected loss. Zacks: Q4 results
• Positive Sentiment: Management highlighted market expansion and revenue acceleration on the earnings call, which supports ongoing growth expectations for newborn hearing-screening adoption. Earnings call transcript
• Neutral Sentiment: FY2026 revenue guidance of $111.0M–$115.0M was issued, roughly in line with the Street estimate (~$112.7M) — guidance supports growth but isn’t a clear upside surprise. (Press release/earnings coverage.)
• Neutral Sentiment: Balance-sheet strength: very high current and quick ratios indicate ample liquidity, reducing short-term financing risk. (See filings/coverage.)
• Negative Sentiment: Insider selling: Director Josef Parvizi sold 16,714 shares (recently continued a pattern of sales), which can be viewed negatively by some investors. Insider selling report
• Negative Sentiment: Company remains unprofitable with a negative net margin (~‑63%), negative ROE, and an expected full‑year EPS loss — profitability timeline remains a key risk for valuation. Business Insider: results summary
• Negative Sentiment: Mixed analyst moves — at least one price-target cut alongside continued buy ratings elsewhere creates divergent expectations that can increase volatility. (Analyst coverage summarized in public filings/press coverage.)

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.